IPO
Company Profile
Clinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.
Founded 2018Alameda, CaliforniaSCTX
Compare with
Scribe Therapeutics FAQ
- Is Scribe Therapeutics publicly traded?
- Yes. Scribe Therapeutics trades under the ticker SCTX.
Coverage Timeline
newest first- Jul 24, 2026IPOScribe Therapeutics Prices Upsized IPO With Sanofi Backing$128.7M Raised→
- Jul 23, 2026IPOScribe Therapeutics Soars In Rare Gene-Editing IPO$128.7M IPO→
- Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→
- Jul 2, 2026IPOScribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPOS-1 filed→
- Jul 2, 2026IPOScribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteUp to $75M IPO→
All Coverage
IPO$128.7M Raised
Scribe Therapeutics Prices Upsized IPO With Sanofi Backing
Gene-editing biotech Scribe Therapeutics priced an upsized IPO at $15 per share, raising $128.7 million with Sanofi as a strategic anchor investor, the first gene-editing IPO in over two years.
IPO
Scribe Therapeutics Soars In Rare Gene-Editing IPO
IPO$128.7M IPO
Scribe Therapeutics Soars In Rare Gene-Editing IPO
Scribe Therapeutics priced an upsized $128.7 million IPO and surged in its Nasdaq debut, a rare early-stage listing for a gene-editing biotech in a market that has favored de-risked, later-stage companies.
IPO
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.
IPO
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
IPOS-1 filed
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
Scribe Therapeutics filed its S-1 with the SEC on July 2, seeking to list on the Nasdaq Global Market under the ticker 'SCTX.' The clinical-stage biotech, co-founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna, has raised roughly $150 million in equity financing since 2017 and is advancing STX-1150 -- an epigenetic-silencing CRISPR candidate for cardiovascular disease -- through an Australian first-in-human trial, while disclosing only $49.7 million in cash and marketable securities against a $175.1 million accumulated deficit.
IPO
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
IPOUp to $75M IPO
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
Scribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.